| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $105K | -29.2% | +16.1% |
| SG&A Expense | $281K | -26.2% | +5.0% |
| Operating Income | -$482K | +22.7% | -9.0% |
| Net Income | -$482K | +22.7% | -9.9% |
| EPS (Basic) | $0.00 | — | — |
| EPS (Diluted) | $0.00 | — | — |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.3M | +18.7% | -47.5% |
| Current Assets | $1.3M | +14.0% | -47.3% |
| Total Assets | $1.3M | +13.7% | -47.0% |
| Current Liabilities | $7K | -40.9% | +100.4% |
| Stockholders' Equity | -$2.1M | +7.3% | -120.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.4M | — | — |
| Financing Cash Flow | $615K | — | — |